Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor John Isaacs.

Newcastle AuthorsTitleYearFull text
Dr Arthur Pratt
Professor John Isaacs
Dr Elena Nikiphorou
Association between social deprivation and disease activity in rheumatoid arthritis: a systematic literature review2022
Dr Faye Cooles
Dr Jessica Tarn
Dr Dennis Lendrem
Najib Naamane
Alice Lin
et al.
Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming2022
Professor John Isaacs
Sarah Brockbank
Dr Ayako Pedersen
Professor Catharien Hilkens
Dr Amy Anderson
et al.
RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients2022
Dr Faye Cooles
Professor John Isaacs
The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease2022
Professor James Wason
Dr Arthur Pratt
Professor John Isaacs
The role of comorbidities alongside patient and disease characteristics on long-term disease activity in RA using UK inception cohort data2022
Dr Fiona Rayner
Dr Amy Anderson
Dr Ken Baker
Professor Christopher Buckley
Dr Bernard Dyke
et al.
BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study2021
Dr Ken Baker
JASMINE Sim
Professor John Isaacs
Biomarkers of tolerance in immune-mediated inflammatory diseases: a new era in clinical management?2021
Professor John Isaacs
Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials2021
Professor John Isaacs
Correction to: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment (Arthritis Research & Therapy, (2021), 23, 1, (80), 10.1186/s13075-021-02451-9)2021
Professor John Isaacs
EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-192021
Dr Ken Baker
Dr Arthur Pratt
Professor John Isaacs
Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Disease Flare in Patients with Rheumatoid Arthritis2021
Professor John Isaacs
Immunogenicity of biologic agents in rheumatology2021
Dr Dennis Lendrem
Professor John Isaacs
Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma2021
Dr Dag Aarsland
Professor John O'Brien
Dr Clive Ballard
Professor John Isaacs
Professor Alan Thomas
et al.
Mild cognitive impairment: the Manchester consensus2021
Dr Nicola Maney
Dr Ben Barron-Millar
Dr Christopher Carey
Ian Herron
Dr Amy Anderson
et al.
Pim Kinases as Therapeutic Targets in Early Rheumatoid Arthritis2021
Professor James Wason
Dr Arthur Pratt
Professor John Isaacs
Dr Elena Nikiphorou
Predictors of poor function in RA based on two prospective UK inception cohorts. Do comorbidities matter?2021
Professor John Isaacs
Dr Arthur Pratt
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial2021
Dr Andrew Porter
Dr Dennis Lendrem
Professor John Isaacs
Robust optimization of SWATH-MS workflow for human blood serum proteome analysis using a quality by design approach2021
Dr Arthur Pratt
Dr Stefan Siebert
Mike Cole
Dr Deborah Stocken
Amy Cranston
et al.
Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial2021
Dr Arthur Pratt
Professor John Isaacs
Dr Elena Nikiphorou
The use and context of the term 'multimorbidity' in rheumatoid arthritis: A systematic literature review2021
Mike Cole
Professor Fai Ng
Dr Stefan Siebert
Dr Arthur Pratt
Professor John Isaacs
et al.
TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis2021
Professor John Isaacs
Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment2021
Professor John Isaacs
Why remission is not enough: underlying disease mechanisms in RA that prevent cure2021
Professor John Isaacs
Correction to: Characterization of Creatine Kinase Levels in Tofacitinib‑Treated Patients with Ulcerative Colitis: Results from Clinical Trials (Digestive Diseases and Sciences, (2020), 10.1007/s10620-020-06560-4)2020
Professor John Isaacs
Professor Iain McInnes
EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-22020
Professor John Isaacs
Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents2020
Dr Jessica Tarn
Dr Dennis Lendrem
Professor John Isaacs
In search of pathobiological endotypes: a systems approach to early rheumatoid arthritis2020
Dr Ken Baker
Benjamin Thompson
Dr Dennis Lendrem
Adam Scadeng
Dr Arthur Pratt
et al.
Lack of association between clinical and ultrasound measures of disease activity in rheumatoid arthritis remission2020
Professor John Isaacs
Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic Drugs2020
Alex Clark
Dr Amy Anderson
Dr Nishanthi Thalayasingam
Najib Naamane
Julie Diboll
et al.
Lymphocyte DNA methylation mediates genetic risk at shared immune-mediated disease loci2020
Professor John Isaacs
Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score2020
Dr Dennis Lendrem
Dr Clare Lendrem
Dr Arthur Pratt
Professor John Isaacs
Professor David Jones
et al.
Schrödinger's pipeline and the outsourcing of pharmaceutical innovation2020
Dr Lilian Nwosu
Dr Arthur Pratt
Professor John Isaacs
Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis2020
Professor John Isaacs
Smart battles: Immunosuppression versus immunomodulation in the inflammatory RMDs2020
Dr Stefan Siebert
Dr Arthur Pratt
Dr Deborah Stocken
Dr Miranda Morton
Amy Cranston
et al.
Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial2020
Professor John Isaacs
Professor Iain McInnes
Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities2020
Dr James Stanway
Professor John Isaacs
Tolerance-inducing medicines in autoimmunity: rheumatology and beyond2020
Dr Ken Baker
Professor John Isaacs
Dr Ben Thompson
“Living a normal life”: a qualitative study of patients’ views of medication withdrawal in rheumatoid arthritis2019
Professor John Isaacs
Dr Arthur Pratt
Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol2019
Professor John Isaacs
Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD392019
Dr Clare Lendrem
Dr Dennis Lendrem
Dr Arthur Pratt
Najib Naamane
Dr Peter McMeekin
et al.
Between a ROC and a hard place: Teaching prevalence plots to understand real world biomarker performance in the clinic2019
Adham Mousa
Professor John Isaacs
Dr David Price
Dr Pallav Bhatnagar
Abhishek Joshi
et al.
Brain pseudotumour secondary to Behçet's disease2019
Emeritus Professor Nicol Ferrier
Professor John Isaacs
Dr John Mansfield
Professor Allan Young
Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data2019
Dr Amy Anderson
Dr Nicola Maney
Dr Dennis Lendrem
Julie Diboll
Dr Philip Brown
et al.
Expression of STAT3-regulated genes in circulating CD4+ T cells discriminates rheumatoid arthritis independently of clinical parameters in early arthritis2019
Laura Ridgley
Dr Amy Anderson
Dr Nicola Maney
Najib Naamane
Andrew Skelton
et al.
IL-6 Mediated Transcriptional Programming of Naïve CD4+ T Cells in Early Rheumatoid Arthritis Drives Dysregulated Effector Function2019
Professor John Isaacs
Keratinocyte growth factor impairs human thymic recovery from lymphopenia2019
Dr Matthew Wood
Adam Leckenby
Dr Gary Reynolds
Dr Rachel Spiering
Dr Arthur Pratt
et al.
Macrophage proliferation distinguishes 2 subgroups of knee osteoarthritis patients2019
Professor John Isaacs
Kundan Iqbal
Potential Pharmacologic Targets for the Prevention of Rheumatoid Arthritis2019
Dr Ken Baker
Andrew Skelton
Dr Dennis Lendrem
Adam Scadeng
Dr Ben Thompson
et al.
Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study2019
Kundan Iqbal
Dr Dennis Lendrem
Ben Hargreaves
Professor John Isaacs
Dr Ben Thompson
et al.
Routine musculoskeletal ultrasound findings impact diagnostic decisions maximally in autoantibody-seronegative early arthritis patients2019
Dr Jessica Tarn
Dr Nadia Howard-Tripp
Dr Dennis Lendrem
Andrew Skelton
Dr Katherine James
et al.
Symptom-based stratification of patients with primary Sjögren’s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials2019
Dr Rachel Spiering
Matthew Wood
Anshor Fath
Oliver Eltherington
Dr Amy Anderson
et al.
Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis2019
Dr Chijioke Mosanya
Professor John Isaacs
Tolerising Cellular Therapies: What Is Their Promise for Autoimmune Disease?2019
Professor John Isaacs
Biologic refractory disease in rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis2018
Dr Nishanthi Thalayasingam
Andrew Skelton
Dr Amy Anderson
Alex Clark
Julie Diboll
et al.
CD4+ and B lymphocyte expression quantitative traits at rheumatoid arthritis risk loci in untreated early arthritis: implications for causal gene identification2018
Professor John Isaacs
Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis2018
Dr Ken Baker
Dr Ben Thompson
Dr Dennis Lendrem
Dr Arthur Pratt
Professor John Isaacs
et al.
Lack of association between clinical and ultrasound measures of disease activity in rheumatoid arthritis clinical remission: a cross-sectional analysis2018
Professor John Isaacs
Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC)2018
Dr Rachel Spiering
Professor John Isaacs
Professor Catharien Hilkens
Dr Phillip Lord
Minimum information about T regulatory cells: A step toward reproducibility and standardization2018
Dr Ken Baker
Professor John Isaacs
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?2018
Dr Faye Cooles
Dr Amy Anderson
Andrew Skelton
Dr Arthur Pratt
Professor Iain McInnes
et al.
Phenotypic and transcriptomic analysis of peripheral blood plasmacytoid and conventional dendritic cells in early drug naïve rheumatoid arthritis2018
Dr Ken Baker
Dr Dennis Lendrem
Dr Ben Thompson
Dr Arthur Pratt
Professor John Isaacs
et al.
Predictors of drug-free remission in rheumatoid arthritis: results from the prospective Biomarkers of Remission in Rheumatoid Arthritis (BioRRA) Study2018
Dr Rachel Spiering
Professor John Isaacs
Professor Catharien Hilkens
Targeting of tolerogenic dendritic cells towards heat-shock proteins: A novel therapeutic strategy for autoimmune diseases?2018
Dr Bridget Griffiths
Professor John Isaacs
The EuroMyositis registry: An international collaborative tool to facilitate myositis research2018
Sarah Brockbank
Dr Carl Goodyear
Dr Ayako Pedersen
Professor John Isaacs
Philip Stocks
et al.
The RA-MAP Consortium: a working model for academia-industry collaboration2018
Dr Fiona Rayner
Professor John Isaacs
Therapeutic tolerance in autoimmune disease2018
Dr Ken Baker
Professor John Isaacs
To taper or not to taper non biological DMARDs in RA remission?2018
Professor John Isaacs
Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis2017
Dr Gillian Bell
Dr Amy Anderson
Julie Diboll
Oliver Eltherington
Dr Rachel Harry
et al.
Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis2017
Professor John Isaacs
Clinical trials of biosimilars should become more similar2017
Helen Hanson
Dr Nicola O'Brien
Dr Paul Whybrow
Professor John Isaacs
Dr Tim Rapley
et al.
Drug breakthrough offers hope to arthritis sufferers: qualitative analysis of medical research in UK newspapers2017
Professor John Isaacs
High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort2017
Professor Karim Raza
Dr Arthur Pratt
Helen Hanson
Dr Stefan Siebert
Professor John Isaacs
et al.
Patient and researcher perspectives on facilitating patient and public involvement in rheumatology research2017
Dr Ken Baker
Dr Arthur Pratt
Dr Ben Thompson
Professor John Isaacs
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers2017
Professor John Isaacs
Subcutaneous injection of Adalimumab Trial compared with Control (SCIATiC): A randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica2017
Professor John Isaacs
Dr Arthur Pratt
Synovial tissue research: A state-of-the-art review2017
Dr Faye Cooles
Dr Amy Anderson
Dr Dennis Lendrem
Julie Norris
Dr Arthur Pratt
et al.
The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy2017
Professor John Isaacs
Professor Fiona Matthews
The MRC Framework for the Development, Design and Analysis of Stratified Medicine Research: Enabling Stratified, Precision and Personalised Medicine2017
Professor John Isaacs
The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort2017
Dr Amy Anderson
Dr David Swan
Oliver Eltherington
Dr Arthur Pratt
Dr Gary Reynolds
et al.
Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T-cells partly via TGF-β12017
Joseph Cowell
Matthew Buck
Rebecca Clarke
Professor Waldemar Vollmer
Dr Daniela Vollmer
et al.
Traceless-Cleavage of Protein-Biotin Conjugates Under Biologically-Compatible Conditions2017
Dr Arthur Pratt
Dr Amy Anderson
Professor John Isaacs
Bcl-3 in CD4+ T Cell–Mediated Rheumatoid Arthritis Pathogenesis: Comment on the Article by Meguro et al2016
Professor John Isaacs
Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody2016
Dr Arthur Pratt
Dr Amy Anderson
Professor John Isaacs
Julie Diboll
Dr Nishanthi Thalayasingam
et al.
Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q232016
Professor Ioakim Spyridopoulos
Dr Carmen Martin-Ruiz
Professor Catharien Hilkens
Mohammad Yadegarfar
Professor John Isaacs
et al.
CMV-seropositivity and T-cell senescence predict increased cardiovascular mortality in octogenarians - results from the Newcastle 85+ study2016
Dr Arthur Pratt
Dr Dennis Lendrem
Ben Hargreaves
Professor John Isaacs
Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data2016
Professor Christopher Buckley
Professor John Isaacs
Cytokines in rheumatoid arthritis - shaping the immunological landscape2016
Professor John Isaacs
Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels2016
Professor John Isaacs
Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis2016
Helen Hanson
Professor John Isaacs
Dr Lesley Kay
Dr Dennis Lendrem
Dr Nicola O'Brien
et al.
Experiences of staff and patients in relation to clinical research recruitment and involvement: a qualitative study2016
Dr Arthur Pratt
Dr Amy Anderson
Julie Diboll
Andrew Skelton
Dr Dennis Lendrem
et al.
Identification of novel expression quantitative trait loci in CD4+ T cells of untreated early arthritis patients2016
Professor John Isaacs
Identifying factors which influence the selection of anti-TNF treatment in patients with rheumatoid arthritis in England2016
Dr Amy Anderson
Dr Arthur Pratt
Dr John Doran
Christine Routledge
Ben Hargreaves
et al.
IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anti-citrullinated peptide antibody-negative rheumatoid arthritis2016
Dr Faye Cooles
Dr Amy Anderson
Dr Rachel Harry
Julie Diboll
Lee Munro
et al.
Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies2016
Dr Philip Brown
Dr Arthur Pratt
Professor John Isaacs
Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers2016
Dr Phillip Lord
Dr Rachel Spiering
Dr Amy Anderson
Julie Diboll
Professor Lindsay Marshall
et al.
Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies2016
Professor John Isaacs
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis2016
Professor John Isaacs
Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort.2016
Dr Gary Reynolds
Dr Arthur Pratt
Dr David Coady
Dr Graham Raftery
Dr Alice Lorenzi
et al.
Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis2016
Dr Dennis Lendrem
Dr Clare Lendrem
Matt Linsley
Ruth Rowland-Jones
Fabio D'Agostino
et al.
Teaching Examples for the Design of Experiments: Geographical Sensitivity and the Self-Fulfilling Prophecy2016
Dr Ken Baker
Benjamin Thompson
Dr Dennis Lendrem
Dr Arthur Pratt
Professor John Isaacs
et al.
Ultrasound measures of synovitis are independent of clinical parameters in the setting of rheumatoid arthritis remission: a cross-sectional analysis.2016
Dr Gary Reynolds
Dr Paul Milne
Dr Venetia Bigley
Professor Matthew Collin
Professor John Isaacs
et al.
Use of the dendritic cell marker, B and T lymphocyte attenuator, to identify functionally distinct subsets of human CD1c+ dendritic cells2016
Dr Katherine James
Shereen Al-Ali
Dr Jessica Tarn
Dr Simon Cockell
Dr Colin Gillespie
et al.
A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren’s Syndrome2015
Professor John Isaacs
Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response2015
Professor John Isaacs
Clinical Utility and Factors Associated with Certolizumab Pegol Drug Levels and Anti-Drug Antibodies in the Long-Term Treatment of Rheumatoid Arthritis2015
Professor John Isaacs
Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis2015
Professor John Isaacs
Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis2015
Dr Arthur Pratt
Ben Hargreaves
Dr Dennis Lendrem
Professor John Isaacs
Components of treatment delay in rheumatoid arthritis differ according to autoantibody status2015
Professor John Isaacs
Decade in review—clinical rheumatology: 10 years of therapeutic advances in the rheumatic diseases2015
Dr Alice Lorenzi
Professor John Isaacs
Defective removal of ribonucleotides from DNA promotes systemic autoimmunity2015
Dr Alice Lorenzi
Professor John Isaacs
Defective removal of ribonucleotides from DNA promotes systemic lupus erythematosus2015
Professor John Isaacs
Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial2015
Shereen Al-Ali
Dr Jessica Tarn
Dr Simon Cockell
Dr Colin Gillespie
Professor John Isaacs
et al.
Gene Set Enrichment Analysis Across Multiple Expression Studies Reveals a Core Subset of Primary Sjögren's Syndrome-Related Genes2015
Professor John Isaacs
Genome-Wide Transcriptional Profiling of Rheumatoid Arthrits Patients: Towards Stratified Medicine2015
Dr Arthur Pratt
Professor John Isaacs
Genotyping in rheumatoid arthritis: a game changer in clinical management?2015
Professor John Isaacs
Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort2015
Professor John Isaacs
Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples2015
Professor John Isaacs
Investigation of Genetic Variants in Predicting Response to Biologic Drugs Used to Treat Rheumatoid Arthritis2015
Dr Dennis Lendrem
Dr Clare Lendrem
Dr David Woods
Ruth Rowland-Jones
Professor John Isaacs
et al.
Lost in Space: Design of Experiments and Scientific Exploration in a Hogarth Universe2015
Professor John Isaacs
Personalized Genetic Medicine: Amino Acid Positions 11, 71 and 74 in HLA-DRB1 Predict Disease Severity, Mortality and Treatment Response in Rheumatoid Arthritis—Multi-Centre Prospective Cohort Studies2015
Dr Dennis Lendrem
Dr Clare Lendrem
Professor John Isaacs
Progression-seeking bias and rational optimism in research and development2015
Dr Arthur Pratt
Ben Hargreaves
Christine Routledge
Lesley Tiffin
Julie Norris
et al.
Reasons for Treatment Delay in Early Rheumatoid Arthritis Differ According to Autoantibody Status2015
Dr Kenneth Baker
Professor John Isaacs
Dr Ben Thompson
Restoring or Threatening a Normal Life: Withdrawing Medication from Patients with Rheumatoid Arthritis in Remission2015
Dr Ken Baker
Professor John Isaacs
Dr Ben Thompson
Restoring or Threatening a Normal Life: Withdrawing Medication from Patients with Rheumatoid Arthritis in Remission2015
Dr Faye Cooles
Dr Arthur Pratt
Dr Dennis Lendrem
Professor Fai Ng
Dr Terry Aspray
et al.
Retrospective analysis of the role of serum vitamin D in early rheumatic disease2015
Professor John Isaacs
Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study2015
Dr Philip Brown
Professor John Isaacs
Rheumatoid Arthritis: An Evolutionary Force in Biologics2015
Dr Laura Jopson
Professor Julia Newton
Dr Jeremy Palmer
Achilleas FLOUDAS
Professor John Isaacs
et al.
RITPBC: B-Cell Depleting Therapy (rituximab) as a treatment for fatigue in Primary Biliary Cirrhosis: study protocol for a randomised controlled trial2015
Dr Laura Jopson
Professor Julia Newton
Denise Howel
Dr Jeremy Palmer
Professor John Isaacs
et al.
RITPBC: B-cell depleting therapy (RITUXIMAB) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial2015
Dr Arthur Pratt
Dr Amy Anderson
Dr Dennis Lendrem
Julie Diboll
Ben Hargreaves
et al.
STAT3-regulated gene expression in circulating CD4+ T cells discriminates RA patients independently of clinical parameters in early arthritis: a validation study.2015
Dr Arthur Pratt
Dr Amy Anderson
Julie Diboll
Andrew Skelton
Ben Hargreaves
et al.
The Importance of IL-6-STAT3 Mediated Activation of Circulating CD4+ T Cells in the Pathogenesis of Early Seronegative Rheumatoid Arthritis: A Validation Study2015
Dr Faye Cooles
Dr Amy Anderson
Professor Catharien Hilkens
Professor John Isaacs
The Interferon Gene Signature in Early Rheumatoid Arthritis Demonstrates No Significant Association with Disease Activity2015
Dr Dennis Lendrem
Dr Clare Lendrem
Professor John Isaacs
Why is it hard to terminate failing projects in pharmaceutical R&D?2015
Harriet Purvis
Dr Amy Anderson
Professor David Young
Professor John Isaacs
Professor Catharien Hilkens
et al.
A Negative Feedback Loop Mediated by STAT3 Limits Human Th17 Responses2014
Professor John Isaacs
Emerita Professor Helen Foster
Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort2014
Dr Gillian Bell
Dr Amy Anderson
Julie Diboll
Dr Rachel Harry
Professor Elaine McColl
et al.
Autologous Tolerogenic Dendritic Cells for Rheumatoid and Inflammatory Arthritis.2014
Dr Gillian Bell
Dr Amy Anderson
Dr Rachel Harry
Julie Diboll
Professor Elaine McColl
et al.
Autologous tolerogenic dendritic cells in rheumatoid and inflammatory arthritis2014
Professor John Isaacs
Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials2014
Dr Dennis Lendrem
Andrew Gray
Professor John Isaacs
Christmas 2014: Going to Extremes. The Darwin Awards: sex differences in idiotic behaviour2014
Professor John Isaacs
Correlating whole genome expression profiling with treatment response in rheumatoid arthritis patients2014
Professor John Isaacs
Differential DNA Methylation Related to Response to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis2014
Professor John Isaacs
Effect of inadequate adherence on clinical outcomes: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort2014
Professor John Isaacs
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial2014
Dr Gary Reynolds
Dr Faye Cooles
Professor John Isaacs
Professor Catharien Hilkens
Emerging immunotherapies for rheumatoid arthritis2014
Professor John Isaacs
Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment2014
Sophie Noblett
Dr Arthur Pratt
Ben Hargreaves
Christine Routledge
Phil Mawson
et al.
IL-6 Driven Stat3 Phophorylation in Circulating Lymphocytes is Specifiv for CD4+ T Cells in Early Rheumatoid Arthritis2014
Professor John Isaacs
Impact of Inadequate Adherence on Clinical Outcomes: Results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Cohort2014
Professor John Isaacs
Emerita Professor Helen Foster
Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis2014
Professor John Isaacs
Influence of Immunogenicity and Drug Levels on the Efficacy of Long-Term Treatment of Rheumatoid Arthritis with Adalimumab and Etanercept: A UK-Based Prospective Study2014
Professor John Isaacs
Influence of Immunogenicity on the Efficacy of Long-Term Treatment of Rheumatoid Arthritis with Adalimumab: A UK-Based Prospective Study2014
Dr Amy Anderson
Christine Routledge
Professor John Isaacs
Dr Arthur Pratt
Investigation of interleukin-6-driven STAT3 signalling in circulating lymphocytes of patients with early rheumatoid arthritis as a route to biomarker discovery2014
Professor John Isaacs
Personalized Genetic Medicine: Amino Acid Positions 11, 71 and 74 in HLA-DRB1 PREDICT Disease Severity, Treatment Response and Mortality in Rheumatoid Arthritis; Multi-Centre Prospective Cohort Studies2014
Dr Amy Anderson
Dr Arthur Pratt
Ben Hargreaves
Philip Brown
Professor John Isaacs
et al.
Phospho-STAT1/3 and Gene Expression Measurement in Circulating CD4+ T Cells As Diagnostic Tools in Early Autoantibody-Negative Rheumatoid Arthritis2014
Dr Amy Anderson
Dr Arthur Pratt
Ben Hargreaves
Philip Brown
Professor John Isaacs
et al.
Phospho-STAT1/3 measurement in circulating CD4+T-cells as a diagnostic tool in early autoantibody-negative rheumatoid arthritis2014
Professor John Isaacs
Predicting Response to Etanercept in Rheumatoid Arthritis Patients Using Whole Genome Expression Profiling2014
Dr Ken Baker
Professor John Isaacs
Prospects for therapeutic tolerance in humans2014
Dr Dennis Lendrem
Dr Clare Lendrem
Professor John Isaacs
R&D Productivity Rides Again?2014
Dr Faye Cooles
Dr Arthur Pratt
Dr Dennis Lendrem
Professor Fai Ng
Dr Terry Aspray
et al.
Retrospective analysis of the role of serum vitamin D in early rheumatic disease2014
Dr Philip Brown
Professor John Isaacs
Rheumatoid arthritis: from palliation to remission in two decades2014
Dr Arthur Pratt
Professor John Isaacs
Seronegative rheumatoid arthritis: Pathogenetic and therapeutic aspects2014
Professor John Isaacs
Testing the role of vitamin D in response to antitumour necrosis factor alpha therapy in a UK cohort: a Mendelian randomisation approach.2014
Professor John Isaacs
The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis2014
Dr Dennis Lendrem
Andrew Gray
Professor John Isaacs
The Darwin Awards: Gender Differences in Idiotic Behaviour2014
Dr Arthur Pratt
Dr Philip Brown
Dr Simon Cockell
Gillian Wilson
Professor John Isaacs
et al.
A CD4+T-Cell Gene Expression Signature Predicts Drug Survival on Methotrexate Monotherapy in Early Rheumatoid Arthritis2013
Professor John Isaacs
Association Of Mean Changes In Laboratory Safety Parameters With C-Reactive Protein At Baseline and Week 12 In Rheumatoid Arthritis Patients Treated With Tofacitinib2013
Dr Gillian Bell
Dr Amy Anderson
Julie Diboll
Dr Rachel Harry
Professor Elaine McColl
et al.
Autologous Tolerogenic Dendritic Cells In Rheumatoid and Inflammatory Arthritis2013
Professor John Isaacs
Can CD11c Expression Successfully Predict Response to Etanercept in Rheumatoid Arthritis Patients?2013
Professor John Isaacs
Differential Methylation Related to Response to Etanercept in Patients with Rheumatoid Arthritis2013
Professor John Isaacs
Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis2013
Professor John Isaacs
Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis2013
Professor John Isaacs
Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis2013
Professor John Isaacs
Impact of IL-6R and IL-6ST Polymorphisms on Response to Anti-TNF Therapy in UK Patients – Results from the Braggss Cohort2013
Dr Amy Anderson
Christine Routledge
Phil Mawson
Professor John Isaacs
Dr Arthur Pratt
et al.
Interleukin-6 driven STAT3 phosphorylation in circulating lymphocytes is specific for CD4 T cells in early rheumatoid arthritis2013
Dr Amy Anderson
Christine Routledge
Phil Mawson
Professor John Isaacs
Dr Arthur Pratt
et al.
Interleukin-6 Driven STAT3 Phosphorylation In Circulating Lymphocytes Is Specific For CD4+ T Cells In Early Rheumatoid Arthritis2013
Dr Arthur Pratt
Dr Alice Lorenzi
Gillian Wilson
Professor John Isaacs
Predicting persistent inflammatory arthritis amongst early arthritis clinic patients in the UK: is musculoskeletal ultrasound required?2013
Professor John Isaacs
Reduced Clinical Improvement in Rheumatoid Arthritis Patients Showing IgG1 Allotype -Infliximab Incompatibility2013
Dr Faye Cooles
Dr Arthur Pratt
Professor Fai Ng
Dr Terry Aspray
Professor John Isaacs
et al.
The Effect Of Vitamin D On Early Rheumatoid Arthritis: A Retrospective Cohort Analysis2013
Professor John Isaacs
The role of biosimilars in the treatment of rheumatic diseases2013
Professor John Isaacs
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: A Randomized Trial2013
Professor John Isaacs
Tofacitinib, An Oral Janus Kinase Inhibitor: Safety Comparison In Patients With Rheumatoid Arthritis and An Inadequate Response To Nonbiologic Or Biologic Disease-Modifying Anti-Rheumatic Drugs2013
Professor Catharien Hilkens
Professor John Isaacs
Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?2013
Dr Faye Cooles
Professor John Isaacs
Dr Amy Anderson
Treg Cells in Rheumatoid Arthritis: An Update2013
Professor John Isaacs
Professor Christopher Buckley
What can rheumatologists learn from translational cancer therapy?2013
Dr Arthur Pratt
Dr Daniel Swan
Dr Sarah Richardson
Gillian Wilson
Professor Catharien Hilkens
et al.
A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly anti-citrullinated peptide antibody-negative disease2012
Dr Arthur Pratt
Dr Philip Brown
Dr Simon Cockell
Gillian Wilson
Professor John Isaacs
et al.
A CD4+T-Cell Gene Expression Signature Predicts Drug Survival On Methotrexate Monotherapy in Early Rheumatoid Arthritis.2012
Dr Arthur Pratt
Dr Alice Lorenzi
Gillian Wilson
Professor John Isaacs
A Pragmatic Musculoskeletal Ultrasound Screening Protocol Does Not Add to a Predictive Algorithm for Persistent Inflammatory Arthritis in a UK Early Arthritis Clinic2012
Professor Simon Pearce
Dr Anna Mitchell
Dr Stuart Bennett
Professor John Isaacs
Dr Bijayeswar Vaidya
et al.
Adrenal Steroidogenesis after B Lymphocyte Depletion Therapy in New-Onset Addison's Disease2012
Dr Gillian Bell
Dr Amy Anderson
Dr Rachel Harry
Dr Jeroen Stoop
Professor Catharien Hilkens
et al.
Autologous tolerogenic dendritic cells in rheumatoid arthritis2012
Mark Houseman
Dr Kate Potter
Nicola Marshall
Dr Rachel Lakey
Emeritus Professor Tim Cawston
et al.
Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up2012
Professor John Isaacs
Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis2012
Professor John Isaacs
Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort2012
Dawn Hiles
Professor John Isaacs
Correlation of CRP haplotypes with response to anti-TNF therapy in UK patients: results from the BRAGGSS cohort2012
Professor David Deehan
Andrew Sprowson
Linda Ferguson
Dr Nilendran Prathalingam
Professor John Isaacs
et al.
Differential Release of Heterogeneous Human Mesenchymal Stem Cell Populations from Haemarthrotic Traumatic Knee Injury2012
Dr Daniel Birchall
Professor Julia Newton
Professor Andrew Blamire
Professor John Isaacs
Disease activity and cognition in rheumatoid arthritis: an open label pilot study2012
Professor John Isaacs
Estimating heritability of response to treatment with anti-TNF biologic agents using linear mixed models2012
Professor John Isaacs
Fc gamma RIIIa Expression on Monocytes in Rheumatoid Arthritis: Role in Immune-Complex Stimulated TNF Production and Non-Response to Methotrexate Therapy2012
Dr Joanna Collerton
Dr Carmen Martin-Ruiz
karen Davies
Professor Catharien Hilkens
Professor John Isaacs
et al.
Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: Cross-sectional findings from the Newcastle 85+ Study2012
Dr Amy Anderson
Dr Alice Lorenzi
Dr Arthur Pratt
Thomas Wooldridge
Julie Diboll
et al.
Immunity 12 years after alemtuzumab in RA: CD5+ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses2012
Professor John Isaacs
Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort2012
Dr Arthur Pratt
Dr Sarah Richardson
Gillian Wilson
Professor Catharien Hilkens
Professor David Young
et al.
A Transcriptional Profile Present in CD4+T-Cells of Patients with Undifferentiated Arthritis Predicts the Future Development of Seronegative Rheumatoid Arthritis and Implicates IL-6 in Disease Evolution2011
Professor John Isaacs
Anti-TNF therapy2011
Dr Gillian Bell
Dr Gary Reynolds
Professor John Isaacs
Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?2011
Dr Arthur Pratt
Dr Alice Lorenzi
Dr Philip Platt
Professor John Isaacs
Does routine musculoskeletal ultrasound use add value to the diagnosis of a RA among early and undifferentiated arthritis patients?2011
Dr Arthur Pratt
Professor John Isaacs
Does testing for circulating autoantibodies against disease-relevant citrullinated antigens add value to the CCP2 assay in diagnosing RA among early undifferenitated arthritis patients?2011
Dr Arthur Pratt
Professor John Isaacs
Does testing for circulating autoantibodies against disease-relevant citrullinated antigens add value to the CCP2 assay in diagnosing RA among early undifferentiated arthritis patients?2011
Professor John Isaacs
Dr Jo Lee
Effect of Tocilizumab on Hematologic Markers Implicates Interleukin-6 Signaling in the Anemia of Rheumatoid Arthritis2011
Dr Ismael Atchia
Dr David Kane
Michael Reed
Professor John Isaacs
Professor Fraser Birrell
et al.
Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis2011
Dr Faye Cooles
Professor Graham Jackson
Professor John Isaacs
Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis2011
Professor John Isaacs
Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients2011
Dr Kate Potter
Professor John Isaacs
Genome-Wide Association Study of Genetic Predictors of Anti-Tumor Necrosis Factor Treatment Efficacy in Rheumatoid Arthritis Identifies Associations With Polymorphisms at Seven Loci2011
Professor John Isaacs
Integrated safety in tocilizumab clinical trials2011
Dr Faye Cooles
Professor John Isaacs
Pathophysiology of rheumatoid arthritis2011
Dr Faye Cooles
Dr Arthur Pratt
Dr Gillian Wilson
Professor John Isaacs
Professor Fai Ng
et al.
Prevalence and diagnostic outcome relating to vitamin D deficiency in new patients presenting to an early arthritis clinic over 12 months2011
Dr Arthur Pratt
Professor John Isaacs
Serotyping for an extended anti-citrullinated peptide autoantibody panel does not add value to CCP2 testing for diagnosing RA in an early undifferentiated arthritis cohort2011
Professor John Isaacs
The need for personalised medicine for rheumatoid arthritis2011
Professor John Isaacs
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis2011
Dr Joanna Cunnington
Dr Geoff Hide
Dr Claire Bracewell
Professor John Isaacs
Dr Philip Platt
et al.
A randomized, double-blind, controlled study of ultrasound-guided corticosteroid injection into the joint of patients with inflammatory arthritis2010
Dr Kate Potter
Professor Heather Cordell
Professor Ann Daly
Professor Derek Mann
Professor John Isaacs
et al.
Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFĸB signalling pathways2010
Professor Catharien Hilkens
Professor John Isaacs
Development of dendritic cell-based immunotherapy for autoimmunity2010
Professor John Isaacs
Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease2010
Dr Faye Cooles
Professor Graham Jackson
Professor John Isaacs
EBV driven lymphoproliferative disease following alemtuzumab (CAMPATH-1H) in refractory polymyositis2010
Professor John Isaacs
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))2010
Dr Rachel Harry
Dr Amy Anderson
Professor John Isaacs
Professor Catharien Hilkens
Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis2010
Emeritus Professor Nicol Ferrier
Professor John Isaacs
Dr John Mansfield
Professor Mark Walker
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls2010
Professor Fai Ng
Professor John Isaacs
Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis2010
Dr Kate Potter
Professor John Isaacs
Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment2010
Harriet Purvis
Dr Jeroen Stoop
Professor Jelena Mann
Steven Woods
Anne Kozijn
et al.
Low strength T-cell activation promotes Th17 responses2010
Dr Jeroen Stoop
Professor Jelena Mann
Steven Woods
Anne Kozijn
Professor Sophie Hambleton
et al.
Low-strength T-cell activation promotes Th17 responses2010
Dr Arthur Pratt
Dr Daniel Swan
Dr Sarah Richardson
Professor Catharien Hilkens
Professor David Young
et al.
Peripheral Blood CD4 T Cell Gene Expression Profiles as Predictive Biomarkers in Early Arthritis2010
Professor Heather Cordell
Professor John Isaacs
Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response2010
Dr Susan Tudhope
Dr Alexei von Delwig
Dr Jane Falconer
Dr Arthur Pratt
Professor John Isaacs
et al.
Profound invariant natural killer T-cell deficiency in inflammatory arthritis2010
Professor John Isaacs
Rheumatoid Arthritis Risk Allele PTPRC Is Also Associated With Response to Anti-Tumor Necrosis Factor alpha Therapy2010
Professor John Isaacs
Rheumatoid factor (RF) oranti-cyclic citrullinated peptide (aCCP) seropositivity in rheumatoid arthritis (RA) patients may enhance clinical response to rituximab2010
Professor John Isaacs
Rituximab plus Methotrexate (MTX) is effective in a subset of patients with early rheumatoid arthritis (RA) and characteristics associated with poor outcomes: an analysis from the image study2010
Professor John Isaacs
The changing face of rheumatoid arthritis: sustained remission for all?2010
Dr Jeroen Stoop
Dr Rachel Harry
Dr Alexei von Delwig
Professor John Isaacs
Professor John Robinson
et al.
Therapeutic Effect of Tolerogenic Dendritic Cells in Established Collagen-Induced Arthritis Is Associated With a Reduction in Th17 Responses2010
Professor John Isaacs
Tolerogenic dendritic cells: a new treatment for rheumatoid arthritis?2010
Professor John Isaacs
Professor Patrick Chinnery
Translating cutting edge science into novel and effective therapies2010
Dr Faye Cooles
Professor John Isaacs
Treating to re-establish tolerance in inflammatory arthritis - lessons from other diseases2010
Helen Baldwin
Dr Toshiko Ihara
Professor John Isaacs
Professor Catharien Hilkens
Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis2010
Professor John Isaacs
[Meeting Abstract] Cost Effectiveness of Biological Therapeutic Sequences for Rheumatoid Arthritis in the UK2009
Dr Arthur Pratt
Dr Daniel Swan
Professor David Young
Professor Catharien Hilkens
Professor John Isaacs
et al.
A High-Throughput Transcriptomics Approach to Biomarker Discover in Early Arthritis2009
Dr Rachel Lakey
Emeritus Professor Drew Rowan
Professor John Isaacs
Emeritus Professor Tim Cawston
Professor Catharien Hilkens
et al.
A novel paradigm for dendritic cells as effectors of cartilage destruction2009
Professor John Isaacs
Animal models in infection and inflammation - Chance and necessity2009
Professor John Isaacs
Antibody engineering to develop new antirheumatic therapies2009
Dr Kate Potter
Professor John Isaacs
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis2009
Dr Claire Bracewell
Professor John Isaacs
Professor Fai Ng
Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis2009
Julie Diboll
Professor John Isaacs
Professor Fai Ng
CD4+T Cell Responses to Autoantigens in Patients with Rheumatoid Arthritis2009
Dr Alice Lorenzi
Dr Angela Patterson
Dr Arthur Pratt
Dr Matthew Jefferson
Professor John Isaacs
et al.
Corrigendum to "Determination of thymic function directly from peripheral blood: A validated modification to an established method" [J. Immunol. Methods 2008 339(2):185-94] (DOI:10.1016/j.jim.2008.09.013)2009
Dr Arthur Pratt
Professor John Isaacs
Current concepts in the pathogenesis of early rheumatoid arthritis2009
Dr Kate Potter
Professor John Isaacs
Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients2009
Dr Amy Anderson
Dr David Swan
Bethan Sayers
Dr Rachel Harry
Dr Angela Patterson
et al.
LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells2009
Dr Ismael Atchia
Dr David Kane
Michael Reed
Professor John Isaacs
Professor Fraser Birrell
et al.
Musculoskeletal ultrasound predicts predicts response to corticosteroid injection in moderate-severe hip osteoarthritis2009
Professor John Isaacs
Dr Amy Anderson
Regulatory T cells and autoimmunity2009
Emeritus Professor David Bates
Professor John Isaacs
Should neurologists wait and see or see and treat RRMS?2009
Dr Arthur Pratt
Professor John Isaacs
The clinical utility of a rule for predicting rheumatoid arthritis in patients with early undifferentiated arthritis: comment on the article by van der Helm-van Mil et al2009
Professor John Isaacs
Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists2009
Dr Alice Lorenzi
Emerita Professor Helen Foster
Professor John Isaacs
Thymic function and immune senescence in juvenile idiopathic arthritis: comment on the article by Prelog et al2009
Dr Alice Lorenzi
Dr Amy Anderson
Dr Jonathan Catterall
Dr Angela Patterson
Emerita Professor Helen Foster
et al.
Thymic function in juvenile idiopathic arthritis2009
Dr Kate Potter
Professor John Isaacs
Variation in the CD226 Gene Predicts Response to Anti-TNF Therapy in Rheumatoid Arthritis2009
Professor John Isaacs
Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'?2009
Professor John Isaacs
A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis2008
Alistair Brown
Professor Jaap Van Laar
Professor John Isaacs
Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse.2008
Dr Ben Thompson
Emeritus Professor Nick Europe-Finner
Dr James Miller
Professor John Isaacs
Alemtuzumab (Campath-1H) for treatment of refractory polymyositis2008
Dr Kate Potter
Professor John Isaacs
Association of the tumour necosis factor -308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis2008
Dr Kate Potter
Professor John Isaacs
Complex genetic relationship of the TNF locus with response to anti-TNF agents in the treatment of rheumatoid arthritis2008
Emeritus Professor Mike Sir Michael Rawlins
Dr Angela Patterson
Dr Arthur Pratt
Dr Matthew Jefferson
Professor John Isaacs
et al.
Determination of thymic function directly from peripheral blood: a validated modification to an established method2008
Dr Rachel Harry
Dr Amy Anderson
Dr Graham Raftery
Professor John Isaacs
Professor Catharien Hilkens
et al.
Development of clinical-grade tolerogenic dendritic cells for the treatment of rheumatoid arthritis2008
Dr Amy Anderson
Bethan Sayers
Professor Muzlifah Haniffa
Dr David Swan
Julie Diboll
et al.
Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells2008
Dr Mahmad Atchia
Dr David Kane
Professor John Isaacs
Professor Fraser Birrell
Efficacy of a single ultrasound guided injection in hip osteoarthritis2008
Professor John Isaacs
FCGR3A is associated with autoantibody positive rheumatoid arthritis in a large UK Caucasian population2008
Professor John Isaacs
From bench to bedside in rheumatology - seize the moment2008
Dr Kate Potter
Professor John Isaacs
Identification of single nucleotide polymorphisms associated with response to anti-tumour necrosis factor treatment2008
Dr Jeroen Stoop
Dr Alexei von Delwig
Professor John Isaacs
Professor John Robinson
Professor Catharien Hilkens
et al.
Immunotherapy with tolerogenic dendritic cells inhibits the progression of collagen-induced arthritis2008
Dr Alexei von Delwig
Dr Arthur Pratt
Dr Susan Tudhope
Professor John Isaacs
Professor Fai Ng
et al.
Invariant natural killer T (iNKT) cells in early rheumatoid arthritis (RA)2008
Dr Alice Lorenzi
Professor John Isaacs
Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: Twelve-year outcomes2008
Professor John Isaacs
Rituximab and abatacept for rheumatoid arthritis2008
Dr Alexei von Delwig
Dr Susan Tudhope
Dr Arthur Pratt
Professor John Isaacs
Dr Desa Lilic
et al.
The role of invariant natural killer T (iNKT) cells in rheumatoid arthritis2008
Professor John Isaacs
The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab)2008
Professor John Isaacs
Therapeutic T-cell manipulation in rheumatoid arthritis: Past, present and future2008
Dr Alice Lorenzi
Emerita Professor Helen Foster
Professor John Isaacs
Thymic function and immune senescence in juvenile idiopathic arthritis2008
Dr Alice Lorenzi
Dr Amy Anderson
Dr Jonathan Catterall
Dr Angela Patterson
Emerita Professor Helen Foster
et al.
Thymic function in juvenile idiopathic arthritis2008
Dr Amy Anderson
Bethan Sayers
Dr David Swan
Professor John Isaacs
Professor Catharien Hilkens
et al.
Tolerogenic dendritic cell therapy for rheumatoid arthritis2008
Dr Amy Anderson
Professor John Isaacs
Tregs and rheumatoid arthritis2008
Professor Muzlifah Haniffa
Dr Xiao Wang
Dr Udo Holtick
Dr Michelle Rae
Professor John Isaacs
et al.
Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells2007
Professor John Isaacs
Biologic therapies in rheumatology: Lessons learned, future directions2007
Dr Mohammed Ali
Professor John Isaacs
Differential display reverse transcription-polymerase chain reaction to identify novel biomolecules in arthritis research2007
Professor Fai Ng
Professor John Isaacs
From mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic2007
Professor Fai Ng
Professor John Isaacs
From mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic2007
Bethan Sayers
Professor Muzlifah Haniffa
Julie Diboll
Professor John Isaacs
Professor Catharien Hilkens
et al.
Generation of dexamethasone and vitamin D3-treated human monocyte-derived dendritic cells with tolerogenic properties2007
Dr Xiao Wang
Dr Udo Holtick
Suzanne Alshemali
Professor Nick Reynolds
Professor Anne Dickinson
et al.
Human dermal broblasts ameliorate in vitro graft-versushost reactions and are functionally indistinguishable from bone marrow mesenchymal stromal cells2007
Professor John Isaacs
Repeat treatment with rituximab improves physical function and quality of life in patients with rheumatoid arthritis and an inadequate response to TNF inhibitors2007
Professor Mark Walker
Professor John Isaacs
Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes2007
Professor John Isaacs
T cell immunomodulation-the Holy Grail of therapeutic tolerance2007
Dr Alexei von Delwig
Dr Fraser Charlton
Professor John Isaacs
Professor John Robinson
T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice2007
Professor John Isaacs
Targeting B cells across the rheumatic diseases2007
Dr Amy Anderson
Bethan Sayers
Julie Diboll
Professor John Isaacs
Professor Catharien Hilkens
et al.
Tolerogenic dendritic cells differentially modulate naïve and memory CD4+ T cells2007
Professor John Allen
Elizabeth Kokkinos
Emeritus Professor Alan Murray
Emeritus Professor Brian Diffey
Dr Simon Meggitt
et al.
Assessment of skin fluorescence characteristics in systemic sclerosis2006
Professor John Isaacs
Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis2006
Alistair Brown
Professor John Isaacs
Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood2006
Dr Alexei von Delwig
Professor John Isaacs
Professor Jeremy Lakey
Professor John Robinson
Febrile temperatures enhance antigen processing of type II collagen for presentation to CD4 T cells.2006
Dr Deborah Thomas
Professor John Isaacs
Dr Peter Hamilton
Guidelines on the management of massive blood loss2006
Alistair Brown
Professor John Isaacs
IL-7 modulates CD4(+)CD25(high) regulatory T-cell function2006
Professor John Isaacs
Dr Peter Dawes
Improved quality of life with rituximab plus methotrexate in patients with active rheumatoid arthritis who experienced inadequate response to one or more anti-TNF alpha therapies2006
Dr Alexei von Delwig
Professor Catharien Hilkens
Professor John Isaacs
Dr Helen Robertson
Professor John Robinson
et al.
Inhibition of macropinocytosis blocks antigen presentation of type II collagen in vitro and in vivo in HLA-DR1 transgenic mice2006
Dr Alice Lorenzi
Dr Angela Patterson
Professor John Isaacs
Measuring thymic function in systemic lupus erythematosus2006
Alistair Brown
Professor John Isaacs
Molecualr mechanism for the accumulation of abnormal T-cells in RA patients in clinical remission: Late atypical cells2006
Alistair Brown
Professor John Isaacs
Molecular mechanism for the persistence of abnormal T-cells in RA patients in clinical remission: Inflammation related cells2006
Professor John Isaacs
Repeat treatment with rituximab improves physical function and quality of life in patients with rheumatoid arthritis and an inadequate response to tnf inhibitors2006
Professor John Isaacs
Repeat treatment with rituximab improves physical function and quality of life in patients with rheumatoid arthritis and an inadequate response to TNF inhibitors2006
Professor John Isaacs
Rheumatology Highlights 2005-062006
Dr Alexei von Delwig
Professor John Isaacs
Dr Norman Balfour-McKie
Professor John Robinson
The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model2006
Professor Simi Ali
Dr Helen Robertson
Professor John Isaacs
Professor John Kirby
A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation2005
Dr Alice Lorenzi
Dr Angela Patterson
Professor John Isaacs
A revised assay for the measurement of T-cell receptor excision circles as a quantitative measure of thymic function in systemic lupus erythematosus2005
Alistair Brown
Professor John Isaacs
A role for IL-7 in regulating CD4(+)CD25(high) regulatory T cells2005
Alistair Brown
Professor John Isaacs
A role for IL-7 in regulating CD4(+)CD25(high) regulatory T cells2005
Dr Bridget Griffiths
Professor John Isaacs
Aglycosyl anti-CD3 monoclonal antibody therapy in rheumatoid arthritis - Results of a pilot safety study2005
Dr Bridget Griffiths
Professor John Isaacs
Analysis of Fcγ receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B2005
Professor John Isaacs
Analysis of the insertion/deletion related polymorphism within T cell antigen receptor β variable genes in primary Sjögren's syndrome2005
Professor John Isaacs
Association of FCGR2A and FC gamma R haplotypes with Spanish polymyalgia rheumatica and giant cell arteritis2005
Professor John Isaacs
Association of FCGR2A and Fc gamma receptor haplotypes with Spanish polymyalgia rheumatica and giant cell arteritis2005
Professor John Isaacs
Association of FCGR3A and FCGR3B haplotypes with rheumatoid arthritis and primary Sjogren's syndrome2005
Dr Alice Lorenzi
Professor John Isaacs
Dr Desa Lilic
CD4+CD25+ T-regulatory cells are decreased in patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy [1]2005
Bethan Sayers
Professor Muzlifah Haniffa
Julie Diboll
Professor John Isaacs
Professor Catharien Hilkens
et al.
Generation of dexamethasone and vitamin D3 treated human monocyte derived dendritic cells with tolerogenic properties2005
Dr Alexei von Delwig
Professor John Isaacs
Professor John Robinson
Human type II collagen is processed in lysosomal compartments of macrophages for presentation of the glycosylated arthritogenic epitope hCII(259-273) to CD4 T cells in HLA-DR1 transgenic mice2005
Professor John Isaacs
Improvement of T-cell function in RA patients in clinical remission is associated with the recovery of IL-7 expression and depends on a familial history of RA2005
Professor John Isaacs
Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis2005
Professor John Isaacs
Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis2005
Dr Elspeth Wise
Professor John Isaacs
Management of rheumatoid arthritis in primary care - An educational need?2005
Professor John Isaacs
Professor Jaap Van Laar
Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration2005
Professor John Isaacs
T-bet expression in RA patients with early, DMARDs naive disease is low and correlates with low levels of IL-7 and T-cell dysfunctions2005
Professor John Isaacs
The persistence of abnormal T-cell differentiation patterns predicts relapse in rheumatoid arthritis patients with controlled disease2005
Dr Alexei von Delwig
Professor John Isaacs
Professor John Robinson
The role of uptake and intracellular trafficking of type II collagen in presentation of the glycosylated arthritogenic epitope CII259-273, to CD4 T cells in HLA-DR1 transgenic mice2005
Professor John Isaacs
The signaling signature downstream of the Notch receptor in CD4+CD25(high) regulatory T-cells in RA defines anergic cells: Insight into resistance to anti-TNF therapies2005
Professor John Isaacs
The signalling signature downstream of the notch receptor in CD4(+)CD25(high) regulatory T cells in RA defines anergic cells: insight into resistance to anti-tumour necrosis factor therapies2005
Dr Alice Lorenzi
Kathryn Walker
Dr Angela Patterson
Dr Bridget Griffiths
Professor John Isaacs
et al.
Thymic function is impaired in patients with a variety of autoimmune diseases2005
Dr Mark Baker
Professor John Isaacs
Dr Peter Fawcett
Emeritus Professor David Bates
Treatment of stiff person syndrome with rituximab2005
Professor John Isaacs
Anti-TNFα Therapy Modulates the Phenotype of Peripheral Blood CD4+ T Cells in Patients with Posterior Segment Intraocular Inflammation2004
Paul Emery
Professor John Isaacs
Fcγ receptors are critical modulators of inflammation within the synovium: Comment on the article by Blom et al2004
Professor John Isaacs
Immune reconstitution2004
Alistair Brown
Dr Prakash Patel
Professor Jaap Van Laar
Professor John Isaacs
Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia2004
Dr Alexei von Delwig
Professor John Isaacs
Professor John Robinson
Mechanisms of MHC class II-restricted antigen processing and presentation of human type II collagen in antigen-presenting cells from humanized DR1 transgenic mice2004
Professor John Isaacs
Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis2004
Professor John Isaacs
Rheumatology Highlights 2003/042004
Professor John Isaacs
Stem cell transplantation for autoimmune disorders: Immune reconstitution2004
Professor John Isaacs
Survival of patients after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis2004
Professor John Isaacs
Targeting B cells with rituximab: An effective and well tolerated treatment for active rheumatoid arthritis (RA)2004
Professor John Isaacs
Association analysis of VDR, alpha-2-macroglobulin, TNFRII, Fc gamma RIIIA and ACE gene polymorphisms in south Asian rheumatoid arthritis patients of the East Midlands, UK2003
Alistair Brown
Professor John Isaacs
CD4+T-Cell TREC-Content in RA Patients in Clinical Remission.2003
Professor John Isaacs
IL-7 Deficiency and Prolonged Therapy-Induced Lymphopenia in Rheumatoid Arthritis.2003
Professor John Isaacs
Long-term immunologic effects of alemtuzumab: Immune reconstitution and immune function after alemtuzumab therapy for autoimmune disease2003
Professor John Isaacs
Neutralizing TNF activity leads to remission in refractory non-infectious uveitis2003
Tein Leong
Professor John Isaacs
Real-time PCR based on SYBR-green flourescence: An alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions2003
Alistair Brown
Professor John Isaacs
Rheumatoid Arthritis is Associated With A Deficit in the CD4(+)CD25(high) Regulatory T Cell Population in Peripheral Blood.2003
Professor Jaap Van Laar
Professor John Isaacs
Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis2002
Professor John Isaacs
From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies2001
Professor Fai Ng
Professor John Isaacs
Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells2001
Professor John Isaacs
Morbidity and Mortality in Rheumatoid Arthritis Patients With Prolonged and Profound Therapy-Induced Lymphopenia2001
Professor John Isaacs
Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced anergy2001
Professor John Isaacs
Professor David Jones
The ninety-fifth annual general meeting of the association of physicians of Great Britain and Ireland 20012001
Dr Bridget Griffiths
Professor John Isaacs
Fcγ receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups2000